{
    "clinical_study": {
        "@rank": "82102", 
        "acronym": "RPED Genetics", 
        "arm_group": [
            {
                "arm_group_label": "AMD subjects with GA and/or RPED", 
                "description": "All subjects will have AMD and GA and/or RPED."
            }, 
            {
                "arm_group_label": "AMD subjects with CNV alone", 
                "description": "All subjects will have the CNV form of AMD only."
            }
        ], 
        "biospec_descr": {
            "textblock": "DNA samples and remnants will be destroyed after analysis."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Patients with AMD will provide cheek cell samples to determine if their is a correlation\n      between genotype (DNA markers) and phenotype (the type of AMD the patient has)."
        }, 
        "brief_title": "Genetic Load and Phenotype in Aggressive AMD", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Age-related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "This study seeks to test individuals who have already progressed to various forms of AMD to\n      evaluate correlations between genetic markers and particular features of AMD including\n      geographic atrophy and pigment epithelial detachments. We hypothesize that patients with\n      more aggressive forms of AMD will have a higher genetic burden contributed by markers in\n      ARMS 2, Complement Factor H (CFH), Complement component 3 (C3), Complement component 2 (C2)\n      , Factor B (FB), or other genetic polymorphisms associated with CNV."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is male or female 50 years of age and older\n\n          -  Subject provides a signed and dated informed consent\n\n          -  Subject agrees to provide two buccal swabs in accordance with this protocol\n\n          -  Diagnosis of CNV secondary to AMD  in at least one eye\n\n        Exclusion Criteria:\n\n          -  Previous sample donation under this protocol\n\n          -  Presence of retinal disease involving the photoreceptors and/or outer retinal layers\n             other than AMD loss such as high myopia, retinal dystrophies, central serous\n             retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer\n             retinal diseases which have been present prior to the age of 50.\n\n          -  Opacities of the ocular media, limitations of pupillary dilation or other problems\n             sufficient to preclude adequate imaging of the posterior segment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with AMD who are or have been treated with anti-VEGF therapy"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01650948", 
            "org_study_id": "SQNM-AMD-106"
        }, 
        "intervention": {
            "arm_group_label": [
                "AMD subjects with GA and/or RPED", 
                "AMD subjects with CNV alone"
            ], 
            "intervention_name": "RetnaGene AMD LDT", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "age-related macular degeneration", 
            "AMD"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Pacific Eye Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40509"
                    }, 
                    "name": "Retina Associates of Kentucky"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Retina"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Central IRB", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The identification of individual genetic markers or a quantitative measure of total genetic burden found to be significantly associated (p value <0.05) with group classification (CNV only versus CNV with GA and/or RPED).", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01650948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sequenom, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sequenom, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}